Pelthos Therapeutics Inc.
PTHS
$25.70
$0.562.23%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 493.01% | 3,860.00% | -58.36% | -213.53% | 745.21% |
| Gross Profit | 1,291.57% | -3,860.00% | 58.36% | 213.53% | -745.21% |
| SG&A Expenses | 1,101.22% | 55.08% | 11.74% | -2.83% | 31.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,011.18% | 83.12% | -5.17% | -52.95% | 58.63% |
| Operating Income | -649.73% | -83.12% | 5.17% | 52.95% | -58.63% |
| Income Before Tax | -885.43% | -94.68% | 23.21% | 52.30% | -19.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -857.99% | -94.68% | 23.21% | 52.30% | -19.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -857.99% | -94.68% | 23.21% | 52.30% | -19.22% |
| EBIT | -649.73% | -83.12% | 5.17% | 52.95% | -58.63% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -81.25% | -75.49% | 41.22% | 84.12% | 79.74% |
| Normalized Basic EPS | -86.45% | -75.48% | 41.22% | 84.12% | 79.74% |
| EPS Diluted | -81.25% | -75.49% | 41.22% | 84.12% | 79.74% |
| Normalized Diluted EPS | -86.45% | -75.48% | 41.22% | 84.12% | 79.74% |
| Average Basic Shares Outstanding | 428.57% | 10.93% | 30.63% | 200.50% | 488.02% |
| Average Diluted Shares Outstanding | 428.57% | 10.93% | 30.63% | 200.50% | 488.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |